|Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial|
AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...
The Lancet 380 (9856), 1829-1839, 2012
|Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial|
JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...
The Lancet 380 (9856), 1819-1828, 2012
|Alemtuzumab vs. interferon beta-1a in early multiple sclerosis|
AJ Coles, DA Compston, KW Selmaj, SL Lake, S Moran, DH Margolin, ...
N Engl J Med 359 (17), 1786-1801, 2008
|McAlpine's multiple sclerosis|
D McAlpine, A Compston
Elsevier Health Sciences, 2005
|Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis|
AJ Coles, MG Wing, P Molyneux, A Paolillo, CM Davie, G Hale, D Miller, ...
Annals of Neurology: Official Journal of the American Neurological …, 1999
|The window of therapeutic opportunity in multiple sclerosis|
AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ...
Journal of neurology 253 (1), 98-108, 2006
|Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis|
AJ Coles, M Wing, S Smith, F Coraddu, S Greer, C Taylor, A Weetman, ...
The Lancet 354 (9191), 1691-1695, 1999
|Disease-relevant autoantibodies in first episode schizophrenia|
MS Zandi, SR Irani, B Lang, P Waters, PB Jones, P McKenna, AJ Coles, ...
Journal of neurology 258 (4), 686-688, 2011
|IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)|
JL Jones, CL Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, ...
The Journal of clinical investigation 119 (7), 2052-2061, 2009
|Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis|
T Moreau, A Coles, M Wing, J Isaacs, G Hale, H Waldmann, A Compston
Brain 119 (1), 225-237, 1996
|Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis|
AL Cox, SAJ Thompson, JL Jones, VH Robertson, G Hale, H Waldmann, ...
European journal of immunology 35 (11), 3332-3342, 2005
|Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial|
AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, A Skoromets, ...
Neurology 78 (14), 1069-1078, 2012
|Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans|
E Schoenmakers, M Agostini, C Mitchell, N Schoenmakers, L Papp, ...
The Journal of clinical investigation 120 (12), 4220-4235, 2010
|Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H|
A Paolillo, AJ Coles, PD Molyneux, M Gawne–Cain, D MacManus, ...
Neurology 53 (4), 751-751, 1999
|Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy|
O Tuohy, L Costelloe, G Hill-Cawthorne, I Bjornson, K Harding, ...
Journal of Neurology, Neurosurgery & Psychiatry 86 (2), 208-215, 2015
|Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort|
M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ...
Neurology 77 (6), 573-579, 2011
|B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis|
SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles
Journal of clinical immunology 30 (1), 99-105, 2010
|Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis|
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
|Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings|
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
|Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity|
JL Jones, JM Anderson, CL Phuah, EJ Fox, K Selmaj, D Margolin, ...
Brain 133 (8), 2232-2247, 2010